Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863155 | 1.00 | TDP1 (0.40) | TDP1CYP1A2KDM4EHTTMGLL | |
| SCHEMBL22228575 | 1.00 | TDP1 (0.40) | TDP1CYP1A2KDM4EHTTMGLL | |
| SCHEMBL16015284 | 0.96 | LMNA (0.39) | TDP1CYP1A2KDM4EHTTMGLL | |
| SCHEMBL17771605 | 0.96 | LMNA (0.39) | TDP1CYP1A2KDM4EHTTMGLL | |
| SCHEMBL22228576 | 0.96 | TDP1 (0.42) | TDP1CYP1A2KDM4EHTTMGLL | |
| N-Methylpiperidine SCHEMBL11878290 | 0.96 | LMNA (0.39) | TDP1CYP1A2KDM4EHTTMGLL | |
| SCHEMBL6238723 | 0.96 | LMNA (0.39) | TDP1CYP1A2KDM4EHTTMGLL | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL4645 | 0.95 | — | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL37881 | 0.95 | — | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL3628998 | 0.95 | TDP1 (0.35) | TDP1CYP1A2KDM4EHTTMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCL, NME4 | TDP1 466/4885CYP1A2 4752/4885KDM4E 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.